Loading…
Stop Tampering of Prescription Pills Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
27pct
1d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Stop Tampering of Prescription Pills Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to deny approval to a new oral opioid (a drug with effects similar to opium, such as morphine) that does not have properties that make the drug significantly more difficult to abuse if an abuse-deterrent drug containing the same opioid is available. The FDA may approve an opioid drug that is not abuse-deterrent if approval is necessary to prevent or alleviate a drug shortage or to address a significant unmet public health need. To be approved by the FDA, a generic version of an abuse-deterrent brand name drug must be at least comparably abuse-deterrent and its active components must not differ in any material respect from the brand name drug. An approved generic drug is not bioequivalent to, and does not have the same therapeutic effect as, a brand name drug that becomes abuse-deterrent unless the generic drug is at least comparably abuse-deterrent. Approval of a generic oral opioid is withdrawn if the brand name drug is not abuse-deterrent and not available and there is an approved abuse-deterrent drug available that contains the same opioid in the same dose. Approval of an oral opioid is withdrawn if the drug is not abuse-deterrent and there is an approved abuse-deterrent drug available that contains the same opioid. Withdrawal of approval may be waived by the FDA for a drug intended for a special needs population. The FDA must delay withdrawal to give the drug sponsor an opportunity to obtain approval for an abuse-deterrent formulation of the drug.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2018 · third_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $164,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Client expense: $147,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Client expense: $178,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2017 · fourth_quarter · Government Issues
Office of Legal Counsel opinions (unintroduced) Access to Congressionally Mandated Reports Act (H.R. 4631) Statutes at Large Modernization Act (H.R. 1729) Equal Access to Congressional Research Service Reports Act of 2016 (H.R. 2335) Financial Services and General Government Appropriations Bill (H.R. 3280) Commerce, Science, Justice Appropriations Bill (H.R. 3267) Legislative Branch Appropriations Bill (H.R. 3162)
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2017 · fourth_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
Client expense: $143,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · third_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $143,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2017 · third_quarter · Government Issues
H.R. 3162, Legislative Branch Appropriations Bill Establishment of a Task Force Concerning the Creation of an Office of Whistleblower Ombudsman, Public Access to CRS Reports, IG Reports Portal, GAO Audit Power Regarding the Intelligence Community, Congressional Research Service Annual Reports, Constitution Annotated, Clearance for HPSCI personal office staff, Staff Designees for HPSCI member H.R. 3267, Commerce, Science, Justice Appropriations Bill Index of Justice Department Office of Legal Counsel Opinions, Updating Foreign Lobbying Reporting and Disclosures(FARA), PACER Audit H.R. 3280, Financial Services and General Government Appropriations Bill Central Access to Congressional Budget Justifications, OIRA Lobbying Transparency H.R. 3219, S. 1519, National Defense Appropriations Act Reporting the number of Congressional staff with classified clearance, OpenGov Data Act H.R. 2335, Equal Access to Congressional Research Service Reports Act of 2016 Access to CRS reports H.R. 1729, Statutes at Large Modernization Act Access to statutes Access to Congressionally Mandated Reports Act (unintroduced) Office of Legal Counsel opinions (unintroduced)
Client expense: $345,000 · Firm income: Not reported
2017 · second_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids H.R. 2430, provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 1049, provisions related to physician education on abuse-deterrent opioid products
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · second_quarter · Government Issues
H.R. 3162, Legislative Branch Appropriations Bill Establishment of a Task Force Concerning the Creation of an Office of Whistleblower Ombudsman, Public Access to CRS Reports, IG Reports Portal, GAO Audit Power Regarding the Intelligence Community, Congressional Research Service Annual Reports, Constitution Annotated, Clearance for HPSCI personal office staff, Staff Designees for HPSCI member H.R. 3267, Commerce, Science, Justice Appropriations Bill Index of Justice Department Office of Legal Counsel Opinions, Updating Foreign Lobbying Reporting and Disclosures(FARA), PACER Audit H.R. 3280, Financial Services and General Government Appropriations Bill Central Access to Congressional Budget Justifications, OIRA Lobbying Transparency H.R. 2335, Equal Access to Congressional Research Service Reports Act of 2016, Access to Congressionally Mandated Reports Act (unintroduced) Office of Legal Counsel opinions (unintroduced), Disclosure of DOJ OLC opinions
Client expense: $430,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), provisions related to incentives for the development of abuse-deterrent opioids Provisions related to the reauthorization of the Prescription Drug User Fee Act 1st Amendment/Communications with payors/off-label policy issues Abuse-deterrent opioid policy issues Pain therapy access policy issues
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| MA |
| Katherine M. Clark | Democratic | MA |
| Robert B. Aderholt | Republican | AL |
| Stephen F. Lynch | Democratic | MA |
| Thomas J. Rooney | Republican | FL |
| Vern Buchanan | Republican | FL |
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of